MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for the treatment of tobacco dependence, announces the filing of a new patent application aimed at strengthening patent protection for NFL-102 and extending it to new therapeutic applications involving neurotransmitters that also play a role in tobacco and nicotine dependence. As the application has yet to be published, the